Ultimovacs ASA: Invitation to Fourth Quarter 2024 Results Webcast Presentation
Generated by AI AgentMarcus Lee
Monday, Jan 27, 2025 2:57 am ET1min read
ASA--
Ultimovacs ASA (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, has invited investors and other stakeholders to a webcast presentation of its fourth quarter 2024 results. The presentation is scheduled for Friday, January 31, 2025, at 09:00 CET. The webcast can be accessed through a link on the company's website (
).
The presentation will provide an update on Ultimovacs' financial performance and progress in its clinical development program. The company's product candidate, UV1, is an off-the-shelf therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and improve cancer treatment efficacy for patients. UV1 triggers an immune response against the shared cancer antigen telomerase, a target present in 85-90% of all cancer indications across disease stages.
Ultimovacs is investigating the safety and efficacy of UV1 in a wide-ranging clinical development program, including various cancer indications and different immunotherapy combinations. The ongoing Phase II program comprises five randomized clinical trials in melanoma, mesothelioma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. More than 640 patients in the U.S., Europe, and Australia are being enrolled in all Phase I and Phase II trials in the current program.
In addition to the clinical development program, Ultimovacs is developing a novel conjugation technology, initially formed to support the expansion of its vaccine pipeline. This flexible conjugation technology has the potential to be broadly applicable to a variety of therapeutic modalities, such as innovative drug conjugates with favorable pharmacological properties, and in multiple disease areas.
Ultimovacs' financial health has been maintained through cash preservation initiatives, extending the anticipated cash runway through the first quarter of 2026. The company's total operating expenses for the third quarter of 2024 were MNOK 28.8, and the total loss for the period was MNOK 25.9. The net negative cash flow from operations was MNOK 42.0 in Q3 2024, and the net decrease in cash and cash equivalents, not including currency effects, was MNOK 40.9 during Q3 2024. Cash and cash equivalents amounted to MNOK 131.0 as per September 30, 2024.
The webcast presentation will be an opportunity for investors to learn more about Ultimovacs' financial performance, progress in its clinical development program, and future plans. The company's CEO, Carlos de Sousa, and CFO, Hans Vassgård Eid, will be available to answer questions throughout the event. The webcast will be archived for replay following the conference call.
For further information, please see Ultimovacs' website (
) or contact the company's investor relations team:
Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
Ultimovacs ASA (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, has invited investors and other stakeholders to a webcast presentation of its fourth quarter 2024 results. The presentation is scheduled for Friday, January 31, 2025, at 09:00 CET. The webcast can be accessed through a link on the company's website (
).The presentation will provide an update on Ultimovacs' financial performance and progress in its clinical development program. The company's product candidate, UV1, is an off-the-shelf therapeutic cancer vaccine designed to enhance the benefits of immunotherapy and improve cancer treatment efficacy for patients. UV1 triggers an immune response against the shared cancer antigen telomerase, a target present in 85-90% of all cancer indications across disease stages.
Ultimovacs is investigating the safety and efficacy of UV1 in a wide-ranging clinical development program, including various cancer indications and different immunotherapy combinations. The ongoing Phase II program comprises five randomized clinical trials in melanoma, mesothelioma, head and neck cancer, ovarian cancer, and non-small cell lung cancer. More than 640 patients in the U.S., Europe, and Australia are being enrolled in all Phase I and Phase II trials in the current program.
In addition to the clinical development program, Ultimovacs is developing a novel conjugation technology, initially formed to support the expansion of its vaccine pipeline. This flexible conjugation technology has the potential to be broadly applicable to a variety of therapeutic modalities, such as innovative drug conjugates with favorable pharmacological properties, and in multiple disease areas.
Ultimovacs' financial health has been maintained through cash preservation initiatives, extending the anticipated cash runway through the first quarter of 2026. The company's total operating expenses for the third quarter of 2024 were MNOK 28.8, and the total loss for the period was MNOK 25.9. The net negative cash flow from operations was MNOK 42.0 in Q3 2024, and the net decrease in cash and cash equivalents, not including currency effects, was MNOK 40.9 during Q3 2024. Cash and cash equivalents amounted to MNOK 131.0 as per September 30, 2024.
The webcast presentation will be an opportunity for investors to learn more about Ultimovacs' financial performance, progress in its clinical development program, and future plans. The company's CEO, Carlos de Sousa, and CFO, Hans Vassgård Eid, will be available to answer questions throughout the event. The webcast will be archived for replay following the conference call.
For further information, please see Ultimovacs' website (
) or contact the company's investor relations team:Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet